...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Diabetes Science and Technology >Use of Blood Glucose Meters Featuring Color Range Indicators Improves Glycemic Control in Patients With Diabetes in Comparison to Blood Glucose Meters Without Color (ACCENTS Study)
【24h】

Use of Blood Glucose Meters Featuring Color Range Indicators Improves Glycemic Control in Patients With Diabetes in Comparison to Blood Glucose Meters Without Color (ACCENTS Study)

机译：与没有颜色的血糖仪相比，使用具有颜色范围指示器的血糖仪可改善糖尿病患者的血糖控制（ACCENTS研究）

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The ability of patients to improve glycemic control depends partly on their ability to interpret and act on blood glucose results. We investigated whether switching people with diabetes to blood glucose meters (BGMs) featuring a color range indicator (CRI) could improve glycemic control compared to remaining on their current BGM without color. Methods: 163 adults with type 1 (T1D) or type 2 diabetes (T2D) and a hemoglobin A1c (A1c) of 7.5-11% were randomized to: One Touch Verio? (Verio), OneTouch Verio Flex? (Flex), or controls remaining on their current BGM. Diabetes nurses had standard conversations about diabetes management with all subjects at baseline. No changes in medication, insulin dosing, or SMBG frequency were recommended. Results: After 12 weeks, subjects who switched to Verio or Flex meters with CRI (n = 108) had a mean change in A1c 0.36% lower than controls (n = 55) ( P = .017). A1c reductions were greatest in T1D subjects (n = 45), with a decrease of 0.50% ( P = .004). T1D subjects using Verio meters (n = 25) contributed a 0.59% reduction compared to controls ( P < .008), whereas T1D subjects using Flex meters (n = 20) had a clinical meaningful reduction in A1c of 0.40% without reaching statistical significance ( P > .05). Verio and Flex users reported taking more action and easier understanding of diabetes management compared to previous BGMs. Conclusions: This study demonstrated that switching patients to BGMs featuring a CRI resulted in improvements in glycemic control compared to subjects using currently marketed BGMs that do not use a CRI.Registration: Clinicaltrials.gov NCT02929654 https://clinicaltrials.gov/ct2/show/NCT02929654
机译：背景：患者改善血糖控制的能力部分取决于他们对血糖结果的解释和作用的能力。我们调查了将糖尿病患者换成具有颜色范围指示器（CRI）的血糖仪（BGM），与保留其当前没有颜色的BGM相比是否可以改善血糖控制。方法：将163名1型（T1D）或2型糖尿病（T2D）且血红蛋白A1c（A1c）为7.5-11％的成人随机分为：一触式Verio？ （Verio），OneTouch Verio Flex？ （Flex），或控件保留在当前BGM上。糖尿病护士与所有受试者在基线时进行了有关糖尿病管理的标准对话。建议不要改变药物，胰岛素剂量或SMBG频率。结果：12周后，使用CRI的Verio或Flex计（n = 108）的受试者的A1c平均变化比对照组（n = 55）低0.36％（P = .017）。在T1D受试者中，A1c下降最大（n = 45），下降了0.50％（P = .004）。与对照组相比，使用Verio量表的T1D受试者（n = 25）减少了0.59％（P <.008），而使用Flex量表的T1D受试者（n = 20）的临床有意义的A1c降低0.40％，而未达到统计学显着（P> .05）。与以前的BGM相比，Verio和Flex用户报告采取了更多的行动并更容易理解糖尿病管理。结论：这项研究表明，与使用不使用CRI的当前市售BGM的受试者相比，将患者换成具有CRI的BGM可以改善血糖控制。注册：Clinicaltrials.gov NCT02929654 https://clinicaltrials.gov/ct2/show / NCT02929654

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号